港股異動 | 康寧傑瑞製藥-B漲4.6% 附屬通過歐盟品質受權人現場檢查
格隆匯2月7日丨 康寧傑瑞製藥-B (9966.HK)高開高走,現報14.94港元,漲幅4.6%,最新總市值138億港元。公司昨日公告稱,全資附屬公司江蘇康寧傑瑞於2月3日已通過歐盟品質受權人“歐盟品質受權人”的現場檢查。本次現場檢查是為了準備KN035(由集團發明的一種抗PD-L1重組人源化單域抗體)的全球臨牀試驗穩定供藥和後續商業化生產。KN035可能是全球第一種可皮下注射的PD-L1抑制劑,具有安全性、便利性、順應性、適用於不適合靜脈輸液的患者等優點。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.